Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB Recruit, an online trial recruitment platform for pharmaceutical and biotechnology companies to identify qualified clinical trial participants in high-need indications, such as Alzheimer's disease; CANTAB Connect that provides digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas from Phases IIV; and Cognition Kit, a digital health platform, which delivers wearable and smartphone apps for data collection to provide engaging digital health solutions for the enhancement of patient engagement, demonstration of treatment efficacy, and understanding of a disease and a patient's response to medication. It also provides CANTAB Connect Research, a research software that offers sensitive digital measures of cognitive function for various areas of brain research; CANTAB Mobile, a touchscreen memory test used in clinical research of Alzheimer's disease; CANTAB BrainHealth, an online digital health assessment tool to measure and monitor mental wellbeing and cognitive performance in the workplace; CANTAB Insight, a medical device that helps to determine an individual's cognitive health; and NeuroVocalix for an automated administration and scoring of well-validated verbal cognitive assessments?on a secure platform. In addition, the company offers a range of expert consultancy and operational management services to optimize clinical trials and cognitive research, which include neuroscience and technical consultancy, study design, data analysis, study and data management, and reports and interpretation. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.

Cambridge Cognition Holdings Plc

OrangeNXT is part of ICT Group and focuses on asset management, cognitive search, and quality assessment. Their services aim to facilitate digital innovation and provide customer-oriented solutions.

OrangeNXT

Cambridge Cognition provides technologies for assessing brain health, focusing on CNS clinical trials. Their platforms are used in-clinic or at home to enhance patient experiences and expedite drug development.

Metric
Company Name	Cambridge Cognition Holdings Plc	OrangeNXT
Symbol	COG
MSH ID	COM:CAMBRIDGECOGNITION	COM:ORANGENXT
Market	STOCKS	PRIVATE
Sector	Healthcare	Technology
Industry	Medical - Healthcare Information Services	Information Technology
Country	GB	NL
Stage
Employee Count	119
Website	cambridgecognition.com	orangenxt.com
LinkedIn
Founders

Metric
Market Cap	178.80K
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	17.22M
Revenue (LTM)
Revenue (NTM)
Gross Profit	13.04M
EBITDA	-1.88M
Operating Income	-2.73M
Net Income	-4.47M
EPS	-0.13
Diluted EPS	-0.13
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.81
Operating Profit Margin	-0.02
EBITDA Margin	-0.11
Net Profit Margin	-0.10
Return on Equity	-0.69
Return on Assets	-0.09
Return on Capital Employed	-0.06

COG

COM:CAMBRIDGECOGNITION

Cambridge Cognition

Last Close

27.70

22/11 17:24

Market Cap

140.30K

Beta: -

Volume Today

91.51K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-40.17
P/B Ratio	172.94
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.54
EV Multiple	49.13

Metric
Days Sales Outstanding
Days Payables Outstanding	1.66K
Days Inventory Outstanding	27.28
Operating Cycle	135.97
Cash Conversion Cycle	-201.71
Asset Turnover	0.95

Metric
Operating Cash Flow	-6.45M
Free Cash Flow	-6.49M
Cash Flow to Debt	0.34
Operating Cash Flow/Sales	-0.24
Free Cash Flow Yield	0.08

Metric
Cash & Equivalents	4.11M
Accounts Receivable	2.85M
Inventory	238.28K
Goodwill
Debt to Capitalization	1.11
Debt to Assets	0.00
Current Ratio	0.90
Quick Ratio	0.63

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue
SG&A to Revenue	0.76